Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547339 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT00547339: Completed Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT00547339 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00547339, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with prostate cancer.
Primary Outcome
Dose-limiting toxicity (DLT) was defined as grade 3 to 5 GI, genito urinary, sexual, or neurologic toxicity attributed to therapy occurring within 90 days of registration using Common Terminology Criteria of Adverse Events(version 3)
Interventions
- RADIATION stereotactic body radiation therapy (SBRT)- 45 Gy
- RADIATION stereotactic body radiation therapy (SBRT) - 47.5 Gy
- RADIATION stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- RADIATION stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2006-07 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 1 |
What the finished NCT00547339 record still lists
NCT00547339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 4 interventions - of which stereotactic body radiation therapy (SBRT)- 45 Gy is the first listed.
NCT00547339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00547339 about?
NCT00547339 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients ...
What is the current status of trial NCT00547339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2006-07. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT00547339?
The interventions under investigation include: stereotactic body radiation therapy (SBRT)- 45 Gy (RADIATION), stereotactic body radiation therapy (SBRT) - 47.5 Gy (RADIATION), stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1) (RADIATION), stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2) (RADIATION).
Who is sponsoring clinical trial NCT00547339?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00547339's enrollment target sits among peer trials
94 615th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia